Sp898

SHOULD ELECTRONIC AND DYE-BASED CHROMOSCOPY REPLACE WHITE-LIGHT COLONOSCOPY AND RANDOM BIOPSIES FOR DYSPLASIA DETECTION IN PATIENTS WITH IBD: YES

Date
May 8, 2023
Explore related products in the following collection:

Society: AGA

This annual session will provide DDW attendees the opportunity to hear opposing viewpoints from leading GI experts on the most challenging issues in clinical gastroenterology and hepatology, in a debate format. This 90-minute symposium will feature 3 debates among "heavyweight" faculty who will provide greater clarity as to how we can apply best evidence to clinical decision-making for these challenging topics. Debates focus on recently published AGA Clinical Practice Updates, which are evidence-based reviews and commentaries that address evolving areas of clinical practice and/or technology. These documents address topics of very high clinical importance, and are published in AGA's flagship journals Gastroenterology and CGH.

Presenter


Tracks

Related Products

Thumbnail for TEMPORAL TRENDS AND RELATIVE RISKS OF INTESTINAL AND EXTRA-INTESTINAL CANCERS IN PERSONS WITH INFLAMMATORY BOWEL DISEASES: A POPULATION-BASED STUDY FROM A LARGE CANADIAN PROVINCE
TEMPORAL TRENDS AND RELATIVE RISKS OF INTESTINAL AND EXTRA-INTESTINAL CANCERS IN PERSONS WITH INFLAMMATORY BOWEL DISEASES: A POPULATION-BASED STUDY FROM A LARGE CANADIAN PROVINCE
BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…
Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA
Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for AUDIENCE POLLING AND Q&A
AUDIENCE POLLING AND Q&A
This annual session will provide DDW attendees the opportunity to hear opposing viewpoints from leading GI experts on the most challenging issues in clinical gastroenterology and hepatology, in a debate format…